Q3 EPS Estimates for Bio-Techne Reduced by Leerink Partnrs

Bio-Techne Co. (NASDAQ:TECH - Free Report) - Research analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Bio-Techne in a report released on Thursday, April 17th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.45 for the quarter, down from their prior forecast of $0.47. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne's Q4 2025 earnings at $0.50 EPS and FY2026 earnings at $2.06 EPS.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%.

Other analysts have also recently issued reports about the company. KeyCorp reissued a "sector weight" rating on shares of Bio-Techne in a report on Wednesday, April 9th. Royal Bank of Canada boosted their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 6th. Citigroup cut their price objective on Bio-Techne from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Scotiabank upped their price objective on Bio-Techne from $88.00 to $90.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 6th. Finally, Evercore ISI started coverage on shares of Bio-Techne in a report on Tuesday, March 18th. They issued an "outperform" rating and a $75.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $81.14.

Bio-Techne Stock Performance

Shares of NASDAQ:TECH traded up $2.01 during midday trading on Friday, hitting $51.09. The stock had a trading volume of 923,913 shares, compared to its average volume of 1,205,495. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $8.08 billion, a PE ratio of 51.61, a P/E/G ratio of 2.88 and a beta of 1.45. Bio-Techne has a 1 year low of $46.01 and a 1 year high of $85.57. The stock has a 50 day moving average price of $58.34 and a two-hundred day moving average price of $68.23.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne's dividend payout ratio (DPR) is presently 32.32%.

Insider Transactions at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the sale, the chief executive officer now owns 39,004 shares of the company's stock, valued at approximately $3,014,619.16. The trade was a 25.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy E. Herr sold 1,860 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares of the company's stock, valued at $130,336.96. The trade was a 48.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.90% of the company's stock.

Hedge Funds Weigh In On Bio-Techne

Hedge funds have recently modified their holdings of the stock. Bradley Foster & Sargent Inc. CT lifted its position in shares of Bio-Techne by 1.5% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 10,799 shares of the biotechnology company's stock worth $778,000 after purchasing an additional 160 shares during the last quarter. UMB Bank n.a. increased its position in shares of Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 168 shares during the period. Verdence Capital Advisors LLC increased its holdings in Bio-Techne by 1.5% in the 4th quarter. Verdence Capital Advisors LLC now owns 11,967 shares of the biotechnology company's stock valued at $862,000 after buying an additional 173 shares during the period. Fifth Third Bancorp raised its stake in shares of Bio-Techne by 2.3% in the 4th quarter. Fifth Third Bancorp now owns 8,394 shares of the biotechnology company's stock valued at $605,000 after buying an additional 189 shares in the last quarter. Finally, Synovus Financial Corp boosted its position in shares of Bio-Techne by 1.5% during the 3rd quarter. Synovus Financial Corp now owns 13,223 shares of the biotechnology company's stock valued at $1,057,000 after acquiring an additional 198 shares in the last quarter. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.